Chroma Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: Oxton United Kingdom (2000)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2004
NCT00692354
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

erlotinib (tarceva) (1 trial)

tefinostat (2 trials)

tosedostat (7 trials)

Drugs in Phase 1 Trials (1)

chr3996 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Hematologic Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Preleukemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 4